



February 5, 2025

Company name:	SanBio Co., Ltd. (Code: 4592 TSE Growth)
Name of representative:	Keita Mori, Representative Director and President
For inquiries, contact:	Yoshihiro Kakutani, Corporate Officer of Management Administration (Phone: 03-6264-3481)

**Conclusion of Contract Manufacturing Agreement with JCR Pharma
for Trial Production of AKUUGO® Suspension for Intracranial Implantation
Toward Commercial Manufacturing**

SanBio Co., Ltd. hereby provides on this matter as per the attached document.



February 5 2025
SanBio Co., Ltd.

Conclusion of Contract Manufacturing Agreement with JCR Pharma for Trial Production of AKUUGO[®] Suspension for Intracranial Implantation Toward Commercial Manufacturing

SanBio Co., Ltd. (Head office: Tokyo, Representative Director and President: Keita Mori) hereby announced on July 31, 2025 that it has entered into a contract manufacturing agreement with JCR Pharmaceuticals Co., Ltd. (Head office: Ashiya, Hyogo Prefecture, Representative Director: Shin Ashida; hereafter, “JCR Pharma”) for the trial production of the human (allogeneic) cell therapy product AKUUGO[®] Suspension for Intracranial Implantation (“AKUUGO[®]”) to assess the feasibility of commercial manufacturing.

By entering into this agreement, SanBio and JCR Pharma aim to explore future contract manufacturing opportunities to ensure the stable production of AKUUGO[®] as a commercial product and to enhance the stability of and diversify its supply framework in anticipation of indication expansion for conditions such as ischemic stroke and market entry into the US.

Keita Mori, Representative Director and President of SanBio, commented:

“AKUUGO[®] is an allogeneic cell therapy that has demonstrated efficacy in treating chronic motor paralysis associated with traumatic brain injury. It is the world’s first and only approved therapy that facilitates the regeneration of brain tissue. Beyond this indication, we are committed to actively advancing its application to other central nervous system disorders with unmet medical needs. With AKUUGO[®]’s demand expected to grow over the medium to long term, we anticipate this agreement will strengthen our supply capacity.”

This matter will have only a minimal impact on the financial performance of the current fiscal year.

About SanBio

SanBio was founded in California, the US in 2001 with the vision of becoming a global leader in the field of regenerative medicine, and is engaged in the regenerative cell business—we research, develop, manufacture, and sell regenerative cell medicines. On July 31 2024, under the Sakigake Designation Program, we obtained conditional and time-limited approval for our mainstay product AKUUGO[®] for the indication of improving chronic motor paralysis associated with traumatic brain injury. Going forward, we will continue focusing our R&D efforts on central nervous system disorders with significant unmet medical needs that cannot be addressed by existing medicine or drugs. The Company is headquartered in Tokyo, Japan and Oakland, California, and additional information about SanBio Group is available at <https://sanbio.com/en/>

[Disclaimer]

This document may contain forward-looking statements such as forecasts, outlooks, goals, and plans related to SanBio group (SanBio Co., Ltd. and SanBio, Inc.) These statements are based on information available to the Company at the time of preparation of this document, including forecasts and other projections. In addition, certain assumptions (hypotheses) are used in making these statements. These statements or assumptions are subjective and may prove to be incorrect in the future or may not be realized in the future. There are several uncertainties and risks that could cause this to happen. Please refer to our financial statements and annual reports for additional information on these matters. The forward-looking statements in this document speak only as of the date of this document (or as otherwise indicated therein), as described above, and we have no obligation or policy to update such information from time to time to keep it current.

For more information, contact:

SanBio Co., Ltd.

Management Administration

Email: info@sanbio.com